{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:10:15Z","timestamp":1789877415699,"version":"4.0.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Treatment with venetoclax + hypomethylating agents (HMAs) is standard-of-care for newly diagnosed (ND) patients with acute myeloid leukemia (AML) aged \u226575 years, or with comorbidities precluding intensive chemotherapy. We describe real-world venetoclax + HMA treatment practices and outcomes in patients with ND AML in the US.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods<\/jats:title>\n                  <jats:p>This retrospective cohort study used an electronic health record-derived, US nationwide, de-identified database, and included adults with ND AML, initiating venetoclax + HMA treatment \u226430 days from diagnosis (June 1, 2018-January 31, 2020). Venetoclax treatment variables included dosing information, schedule modifications, and drug\u2013drug interactions. The median venetoclax + HMA treatment duration and overall survival (OS) from venetoclax initiation to discontinuation, death, or end of follow-up (August 31, 2020) were examined by Kaplan-Meier analyses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 169 patients were included. The median age at diagnosis was 77 years; 85.2% of patients were treated in community practice. Ninety-five of 169 patients (56.2%) had evaluable bone marrow response data following the start of treatment; 53.7% were assessed approximately at the end of cycle 1. Following the first treatment cycle, treatment schedule modifications were recorded in 101 patients and dose changes in 56, primarily due to toxicity. The median treatment duration was 5.2 months; the median OS was 8.6 months (median follow-up was 7.2 months). Venetoclax dose changes did not modify efficacy outcomes, but longer median OS was associated with venetoclax treatment schedule modifications (P = .02).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study reflects early real-world experience with venetoclax + HMAs in a predominantly community setting and emphasizes the importance of appropriate venetoclax management in optimizing patient outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyac135","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T15:29:43Z","timestamp":1659626983000},"page":"907-918","source":"Crossref","is-referenced-by-count":49,"title":["Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9779-6217","authenticated-orcid":false,"given":"Pankit","family":"Vachhani","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Alabama at Birmingham , Birmingham, AL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn M","family":"Flahavan","sequence":"additional","affiliation":[{"name":"Roche Products Ltd ., Welwyn Garden City , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Xu","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd , Basel , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esprit","family":"Ma","sequence":"additional","affiliation":[{"name":"Genentech, Inc. , South San Francisco, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Montez","sequence":"additional","affiliation":[{"name":"Genentech, Inc. , South San Francisco, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anda","family":"Gershon","sequence":"additional","affiliation":[{"name":"Genentech, Inc. , South San Francisco, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maika","family":"Onishi","sequence":"additional","affiliation":[{"name":"Genentech, Inc. , South San Francisco, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Jin","sequence":"additional","affiliation":[{"name":"Genentech, Inc. , South San Francisco, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Ku","sequence":"additional","affiliation":[{"name":"Genentech, Inc. , South San Francisco, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brannon","family":"Flores","sequence":"additional","affiliation":[{"name":"Genentech, Inc. , South San Francisco, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cat N","family":"Bui","sequence":"additional","affiliation":[{"name":"AbbVie, Inc. , North Chicago, IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A","family":"Abbas","sequence":"additional","affiliation":[{"name":"Tennessee Oncology , Nashville, TN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Donnellan","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute, Tennessee Oncology , Nashville, TN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,8,4]]},"reference":[{"issue":"18","key":"2022110514284016700_CIT0001","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"issue":"17","key":"2022110514284016700_CIT0002","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1182\/blood-2011-12-379008","article-title":"Acute myeloid leukemia in the real world: why population-based registries are needed","volume":"119","author":"Juliusson","year":"2012","journal-title":"Blood"},{"key":"2022110514284016700_CIT0003","author":"Board CNE."},{"issue":"4","key":"2022110514284016700_CIT0004","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2022110514284016700_CIT0005","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1182\/blood-2006-04-014324","article-title":"Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B","volume":"108","author":"Fr\u00f6hling","year":"2006","journal-title":"Blood"},{"issue":"15","key":"2022110514284016700_CIT0006","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1002\/cncr.28129","article-title":"Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades","volume":"119","author":"Thein","year":"2013","journal-title":"Cancer"},{"issue":"11","key":"2022110514284016700_CIT0007","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2165\/00002512-200522110-00004","article-title":"Trends in the treatment of acute myeloid leukaemia in the elderly","volume":"22","author":"Lang","year":"2005","journal-title":"Drugs Aging"},{"key":"2022110514284016700_CIT0008","author":"US Food and Drug Administration.","year":"2018"},{"key":"2022110514284016700_CIT0009","author":"AbbVie.","year":"2018"},{"key":"2022110514284016700_CIT0010","author":"AbbVie.","year":"2020"},{"issue":"7","key":"2022110514284016700_CIT0011","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"2022110514284016700_CIT0012","doi-asserted-by":"crossref","first-page":"16","DOI":"10.6004\/jnccn.2021.0002","article-title":"NCCN guidelines insights: Acute myeloid leukemia, version 2.2021","volume":"19","author":"Pollyea","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"2022110514284016700_CIT0013","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"18","key":"2022110514284016700_CIT0014","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1182\/blood-2016-04-711986","article-title":"MPL expression on AML blasts predicts peripheral blood neutropenia and thrombocytopenia","volume":"128","author":"Rauch","year":"2016","journal-title":"Blood"},{"issue":"18","key":"2022110514284016700_CIT0015","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1182\/blood-2016-09-738765","article-title":"Down for the count in acute myeloid leukemia","volume":"128","author":"Goldberg","year":"2016","journal-title":"Blood"},{"issue":"14","key":"2022110514284016700_CIT0016","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1002\/cncr.33508","article-title":"Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia","volume":"127","author":"Rausch","year":"2021","journal-title":"Cancer"},{"issue":"3","key":"2022110514284016700_CIT0017","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with &gt;30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"issue":"21","key":"2022110514284016700_CIT0018","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"2022110514284016700_CIT0019","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"8","key":"2022110514284016700_CIT0020","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"issue":"Suppl. 1","key":"2022110514284016700_CIT0021","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood-2020-134832","article-title":"Cytopenia management in patients with newly diagnosed acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study","volume":"136","author":"Pratz","year":"2020","journal-title":"Blood."},{"key":"2022110514284016700_CIT0022","doi-asserted-by":"crossref","first-page":"212574","DOI":"10.7573\/dic.212574","article-title":"Venetoclax: evidence to date and clinical potential","volume":"8","author":"Ju\u00e1rez-Salcedo","year":"2019","journal-title":"Drugs Context"},{"key":"2022110514284016700_CIT0023","doi-asserted-by":"crossref","first-page":"2040620719882822","DOI":"10.1177\/2040620719882822","article-title":"Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy","volume":"10","author":"Richard-Carpentier","year":"2019","journal-title":"Ther Adv Hematol"},{"issue":"2","key":"2022110514284016700_CIT0024","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","article-title":"Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments","volume":"39","author":"Agarwal","year":"2017","journal-title":"Clin Ther"},{"key":"2022110514284016700_CIT0025","article-title":"Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research","author":"Birnbaum","year":"2020","journal-title":"arXiv"},{"key":"2022110514284016700_CIT0026","article-title":"Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR","author":"Ma","year":"2020","journal-title":"medRxiv"},{"issue":"Suppl. 1","key":"2022110514284016700_CIT0027","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood-2020-134830","article-title":"Treatment patterns and outcomes of patients with newly diagnosed acute myeloid leukemia (AML) treated with hypomethylating agents (HMA) in the United States (US)","volume":"136","author":"Pardee","year":"2020","journal-title":"Blood"},{"issue":"10","key":"2022110514284016700_CIT0028","first-page":"1006","article-title":"method to evaluate scientific evidence in clinical preventive medicine.","volume":"54","author":"Lee","year":"2011","journal-title":"JKMA"},{"key":"2022110514284016700_CIT0029","article-title":"Poster 2328 Comparative effectiveness of venetoclax combinations vs other therapies among patients with newly diagnosed acute myeloid leukemia: Results from the AML Real World Evidence (ARC) Initiative.","author":"Garcia","year":"2021"},{"issue":"1","key":"2022110514284016700_CIT0030","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/hematology.2020000097","article-title":"Practice patterns and outcomes for adults with acute myeloid leukemia receiving care in community vs academic settings","volume":"2020","author":"Halpern","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"25","key":"2022110514284016700_CIT0031","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1200\/JCO.21.00080","article-title":"Harnessing the therapeutic value of venetoclax: a breakthrough therapy in acute myeloid leukemia","volume":"39","author":"Wei","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/11\/907\/46832457\/oyac135.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/11\/907\/46832457\/oyac135.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T14:30:08Z","timestamp":1667658608000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/27\/11\/907\/6655781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,4]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,8,4]]},"published-print":{"date-parts":[[2022,11,3]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac135","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,1]]},"published":{"date-parts":[[2022,8,4]]}}}